Objectif Antibiotics are routinely used in the treatment of lung microbial infections and there is concern about the increasing number of lung pathogens which show antibiotic-resistance. Lung surfactant proteins A and D (SP-A and SP-D) are part of the naturally occurring innate immune system which provides an immediate defence against a wide range of lung pathogens (viruses, bacteria and fungi) and also have an anti-inflammatory forms of allergic reactions. Levels of SP-A -and SP-D fall during certain infections. thus the use of recombinant forms of these proteins may alleviate the need for administration of antibiotics, especially in the very young, ventilated patients and immunocompromised adults (such as AIDS patients). Recombinant forms of SP-A and SP-D will be directly tested as therapeutic agents and also after their addition to lung surfactant preparations which are in clinical use/or trials (which at present lack SP-A and SP-D). The recombinant forms of SP-A and SP-D will be fully characterised and their biological properties assessed by in vitro assays and in animal models of lung infection and inflammation. This will allow the formulation of the optimal recombinant forms of SP-A and SP-D for use in human clinical trials. Champ scientifique natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesbasic medicineimmunologymedical and health scienceshealth sciencesinfectious diseasesRNA virusesHIVmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibioticsmedical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance Programme(s) FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002 Thème(s) 1.1.1.-2. - Key action Control of Infectious Diseases Appel à propositions Data not available Régime de financement CSC - Cost-sharing contracts Coordinateur Medical Research Council (MRC) Contribution de l’UE Aucune donnée Adresse 20 Park Crescent W1N 4AL London Royaume-Uni Voir sur la carte Coût total Aucune donnée Participants (4) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire ALTANA PHARMA A.G. Allemagne Contribution de l’UE Aucune donnée Adresse Byk-Gulden Str. 2 78467 KONSTANZ Voir sur la carte Coût total Aucune donnée UNIVERSIDAD COMPLUTENSE DE MADRID Espagne Contribution de l’UE Aucune donnée Adresse Ciudad Universitaria s/n 28040 MADRID Voir sur la carte Coût total Aucune donnée UNIVERSITY OF SOUTHERN DENMARK - UNIVERSITY OF ODENSE Danemark Contribution de l’UE Aucune donnée Adresse Winsloeevparken 21 5000 ODENSE Voir sur la carte Coût total Aucune donnée UTRECHT UNIVERSITY Pays-Bas Contribution de l’UE Aucune donnée Adresse Yalelaan 1 3584 CL UTRECHT Voir sur la carte Coût total Aucune donnée
